Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Qiagen Ink Colorectal Cancer Option Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Epigenomcs and Qiagen today announced an option agreement allowing Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.

Qiagen has two years to exercise its option under the non-exclusive license granted by Epigenomics. Qiagen also has received a research license covering the mSept9 biomarker and technologies, and it is currently developing sample preparation technology "that meets the requirements for the future broad implementation of methylation-based molecular diagnostics," such as Septin-9 targeted blood testing for colorectal cancer on Qiagen's QIAsymphony platform, Epigenomics said in a statement

Epigenomics is providing expertise and aiding in the collection of clinical specimens during the R&D phase, for which it will receive reimbursement from Qiagen.

Epigenomics also will receive an upfront payment, under the terms of the deal, and a license payment from Qiagen upon exercise of the option. If Qiagen commercializes a test based on Epigenomics' biomarkers and technologies, it will pay Epigenomics royalties on net sales and certain commercial milestone payments if specific revenue targets are reached.

Further financial terms were not disclosed.

The two companies have collaborated since 2005, when they signed a licensing and OEM agreement to develop products for DNA methylation analysis.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.